ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi reported 14.1% YoY revenue growth in Q1 FY27, driven by market diversification and its first proprietary manufacturing facility. Strategy emphasizes backward integration in Latin America and Africa.
Balaxi Pharmaceuticals Ltd reported revenue from operations of ₹80.7 Cr (+14.1% YoY) and net profit of ₹1.3 Cr (+333.3% YoY) for Q1 FY27.